View printer-friendly version << Back Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy Phase 2b Study Aerpio Press Release_Final.pdf 379 KB
View printer-friendly version << Back Aerpio Announces Initiation of Patient Dosing in the TIME-2b Study, a Phase 2b Clinical Trial of Lead Candidate AKB-9778 in Patients with Diabetic Retinopathy Phase 2b Study Aerpio Press Release_Final.pdf 379 KB